Johnson & Johnson (JNJ)

NYSE: JNJ · Real-Time Price · USD

260.35

-1.73 (-0.66%)

At close: Aug 14, 2026, 3:59 PM

260.55

+0.08%

After-hours: 8:00 PM

-0.66% (1D)

Bid	259.56
Market Cap	627.42B
Revenue (ttm)	97.93B
Net Income (ttm)	21.04B
Beta	0.23
EPS (ttm)	8.62
PE Ratio (ttm)	30.2
Forward PE	21.15
P/B (ttm)	7.38
P/S (ttm)	6.41
Earnings Date	Oct 13, 2026

Ask	260.83
Volume	3,928,350
Avg. Volume (20D)	8,140,201
Open	260.65
Previous Close	262.08
Day's Range	259.16 - 261.71
52-Week Range	173.33 - 274.90
Analyst	Buy
Price Target	280 (7.55%)
Dividends	$5.36 (2.05%)
Ex-Dividend Date	Aug 25, 2026

About JNJ

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed th...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date n/a

Employees 138,200

Stock Exchange NYSE

Ticker Symbol JNJ

Website https://www.jnj.com

Full Company Profile

Financial Performance

In 2025, Johnson & Johnson's revenue was 94.19B, an increase of 6.05% compared to the previous year's 88.82B. Earnings were 26.8B, an increase of 90.56%.

Financial Statements

Analyst Forecast

According to 22 analyst ratings, the average rating for JNJ stock is "Buy". The 12-month stock price forecast is 280, which is upside of 7.55% from the latest price.

Stock Forecasts

Earnings Surprise

Johnson & Johnson has released their quarterly earnings on Jul 15, 2026:

Revenue of $25.31B misses estimates by $0, with 6.60% YoY growth.

EPS of 2.9 exceeds estimates by 0.05, with 4.69% YoY growth.

Next Earnings Release

Johnson & Johnson is scheduled to release its earnings on Oct 13, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

4 hours ago · Zacks

This Dividend Aristocrat Posted Record Quarterly Results

Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%. The gain has similarly shown strong outperformance relative to the S&P 500, with recent results driving po...

7 hours ago · Trefis

AbbVie Defends Its Turf, But Leaves One Big Question Open

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

9 hours ago · Simply Wall St.

Johnson & Johnson (JNJ) Stock Looks Cheap On Cash Flow But Rich On Earnings

Johnson & Johnson has delivered a 68.9% total return over the past 5 years, yet its valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while mark...